Scribe Therapeutics Inc. (SCTX)
| Market Cap | 384.83M |
| Revenue (ttm) | 36.28M +86.7% |
| Net Income | -35.73M |
| EPS | -14.64 |
| Shares Out | 18.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149,266 |
| Open | 18.79 |
| Previous Close | 18.36 |
| Day's Range | 18.67 - 22.66 |
| 52-Week Range | 17.31 - 25.49 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 29, 2026 |
About SCTX
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and ... [Read more]
Financial Performance
Financial StatementsNews
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tech...
Opening Day: Scribe Therapeutics makes strong trading debut
Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the market with cardiometabolic programs at the forefront…
Scribe Therapeutics opens at $25, IPO priced at $15 per share
Scribe Therapeutics (SCTX), which priced 8.58M shares at $15.00, describes itself as a clinical-stage biotechnology company engineering CRISPR-based technologies into “purpose-built in vivo genetic me...
Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share
11:21 EDT Scribe Therapeutics (SCTX) indicated to open at $25, IPO priced at $15 per share
Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share
Scribe Therapeutics (SCTX) priced 8.58M shares at $15.00. Leerink, Goldman Sachs, Guggenheim and Wells Fargo acted as joint book running managers for the offering. Scribe Therapeutics is a clinical-st...
Scribe Therapeutics 8.58M share IPO priced at $15.00
The deal guidance is towards the high-end of the $13.,00-$15.00 range. Leerink, Goldman Sachs, Guggenheim and Wells Fargo acted as joint book running managers for the offering. Published first on…
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tech...
Scribe Therapeutics IPO Registration Document (S-1)
Scribe Therapeutics has filed to go public with an IPO on the NASDAQ
Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO
Scribe Therapeutics, a Phase 1 biotech developing CRISPR therapies for cardiovascular diseases, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.